Allena Pharmaceuticals to Participate in Upcoming Investor Conferences in September

NEWTON, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. ALNA, a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in three investor conferences in September:

Baird 2019 Global Healthcare Conference
Date: Thursday, September 5
Time: 7:55 a.m. ET
Location: New York, NY

Morgan Stanley 17^th Annual Global Healthcare Conference
Date: Tuesday, September 10
Location: New York, NY

Ladenburg Thalmann 2019 Healthcare Conference
Date: Tuesday, September 24
Time: 3:30 p.m. ET
Location: New York, NY

Live audio webcasts of the Baird and Ladenburg Thalmann presentations will be available under "Events and Presentations" in the Investors section of the Company's website at www.allenapharma.com. Replays of the webcasts will be available on the Allena website for 30 days following each presentation.

About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena's lead product candidate, reloxaliase, is a first in class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.

Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com

Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com